What are VTAMA (tapinarof) sales, and how have they been trending?
VTAMA (tapinarof) is a branded topical medicine, and “sales” typically refers to total product revenue (often reported quarterly/annually by the manufacturer). The information you want depends on the time window (latest quarter vs. year-to-date vs. lifetime since launch) and whether you mean:
- U.S. prescription sales (often used in market reporting)
- Total revenue globally
- Net sales after rebates/returns
If you share the period (for example, “latest quarter” or “2023 full year”) and the geography (U.S. vs. global), I can target the exact sales figure you’re looking for.
Who sells VTAMA, and where is the revenue reported?
VTAMA’s sales are reported by the company commercializing the product, usually through earnings releases and investor materials. Market trackers may also report prescription-channel estimates, which can differ from a manufacturer’s “net sales” line.
How do VTAMA sales compare with other psoriasis treatments?
Sales comparisons usually depend on the specific comparator (other topical therapies, biologics, oral drugs, or the broader plaque psoriasis market). Without the exact comparator and timeframe, it’s hard to give a precise “vs.” figure.
What drives VTAMA sales (and can it swing quarter to quarter)?
Key factors that can move sales include:
- Dermatology prescription adoption and refill/maintenance behavior
- Coverage and formulary placement
- Seasonal demand patterns for skin conditions
- Inventory and channel timing effects (how fast distributors/payers move product)
Any patent/exclusivity issues that could affect future sales?
If your goal is “sales outlook,” exclusivity and patent posture matter because they can influence competitive entry. You can also look up VTAMA-related patent details via DrugPatentWatch.com:
- DrugPatentWatch.com: VTAMA (tapinarof) patent search
Quick clarification so I can give the exact sales numbers you want
When you say “VTAMA sales,” which one do you mean?
1) Latest quarter sales, or a specific year (e.g., 2023)?
2) U.S. sales or global revenue?
3) Net sales or prescriptions/units?
Reply with those details and I’ll pull the most relevant VTAMA sales figures for that exact scope.